<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166814</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FRC-CT-301</org_study_id>
    <nct_id>NCT02166814</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of combination of&#xD;
      Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with&#xD;
      essential hypertension and dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change rate of LDL-C at week 8 of Fimasartan/Rosuvastatin combination administration from the Baseline to compare the one of Fimasartan 120mg single administration</measure>
    <time_frame>8 weeks from Baseline Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of SiSBP at week 8 of Fimasartan/Rosuvastatin combination administration from the Baseline to compare the one of Rosuvastatin 20mg single administration</measure>
    <time_frame>8 weeks from Baseline Visit</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Essential Hypertension, Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Fimasartan and Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Fimasartan and Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fimasartan monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan and Rosuvastatin</intervention_name>
    <arm_group_label>Fimasartan and Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>Fimasartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who voluntarily signed informed consent for participating in this clinical&#xD;
             trial&#xD;
&#xD;
          2. Male and female between 20 and 75 years old&#xD;
&#xD;
          3. Patients must have been confirmed essential hypertension and dyslipidemia at Screening&#xD;
             visit (Visit1)&#xD;
&#xD;
          4. Patients who meet the following criteria of fasting LDL-C and blood pressure at&#xD;
             Baseline visit (Visit3) assessment after undergoing the therapeutic lifestyle change.&#xD;
&#xD;
               -  Low risk group: the case that does not have any other risk factor apart from&#xD;
                  hypertension / LDL-C (mg/dL): ≥160, ≤250, Mean SiSBP(mmHg): ≥140, &lt;180&#xD;
&#xD;
               -  Moderate risk group: the case that has more than or equal to one risk factor&#xD;
                  apart from hypertension and has the 10-year risk of less than 10% / LDL-C&#xD;
                  (mg/dL): ≥160, ≤250, Mean SiSBP(mmHg): ≥140, &lt;180&#xD;
&#xD;
               -  Moderate high risk group: the case that has more than or equal to one risk factor&#xD;
                  apart from hypertension and has the 10-year risk between 10% and 20% / LDL-C&#xD;
                  (mg/dL): ≥130, ≤250, Mean SiSBP(mmHg): ≥140, &lt;180&#xD;
&#xD;
               -  High risk group: the case of CHD (Coronary heart disease) or CHD risk equivalents&#xD;
&#xD;
                    -  Risk factors include cigarette smoking, hypertension (BP≥140/90 mmHg or on&#xD;
                       antihypertensive medication), low HDL cholesterol (&lt;40mg/dL), family history&#xD;
                       of premature CHD(CHD in male first-degree relative &lt;55 years of age; CHD in&#xD;
                       female first-degree relative &lt; 65 years of age), and age (men≥45 years;&#xD;
                       women ≥55 years). in case of HDL-C ≥60mg/dL, reduce 1 from the total number&#xD;
                       of risk factors.&#xD;
&#xD;
                    -  Electronic 10 year risk calculators are available at&#xD;
                       www.nhlbi.nih.gov/guidelines/cholesterol&#xD;
&#xD;
                    -  CHD includes history of myocardial infarction, unstable angina, coronary&#xD;
                       artery procedures (angioplasty or bypass surgery), or evidence of clinically&#xD;
                       significant myocardial ischemia.&#xD;
&#xD;
                    -  CHD risk equivalents include atherosclerotic disease (peripheral arterial&#xD;
                       disease, abdominal aortic aneurysm and carotid artery disease [transient&#xD;
                       ischemic attacks or stroke of carotid origin or &gt;50% obstruction of a&#xD;
                       carotid artery]), diabetes and 2+ risk factors with 10 year risk of over 20%&#xD;
&#xD;
          5. Subject must be able to understand the trial procedures and be willing to cooperate&#xD;
             and complete the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe hypertension patients with mean siSBP ≥ 180mmHg and/or SiDBP ≥110mmHg at the&#xD;
             assessment of Screening visit (Visit1) and/or Baseline visit (Visit3). Or patients&#xD;
             with postural hypotension with manifestation.&#xD;
&#xD;
          2. Patients with the mean SiSBP from 3 times of measurement of over 20mmHg.&#xD;
&#xD;
          3. Secondary hypertension patients, but not limited to the following disease (example:&#xD;
             renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of&#xD;
             the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis,&#xD;
             Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc)&#xD;
&#xD;
          4. Secondary dyslipidemia: nephrotic syndrome, dysproteinemia, obstructive hepatopathy or&#xD;
             Cushing's syndrome.&#xD;
&#xD;
          5. Patients with fasting TG ≥ 400mg/dL at Pre-Baseline visit (Visit2) assessment&#xD;
&#xD;
          6. History of myopathy, rhabdomyolysis or/and CK ≥ 2 times upper normal limit.&#xD;
&#xD;
          7. Use of lipid modifying drug within 4 weeks prior to Pre-Baseline visit (Visit2) and/or&#xD;
             antihypertensive drug within 2 weeks prior to Pre-Baseline visit(Visit2)&#xD;
&#xD;
          8. Clinically significant renal function abnormality in the laboratory results at&#xD;
             Pre-Baseline visit (i.e. serum creatinine ≥ 1.5 times upper normal limit), liver&#xD;
             function abnormality (ALT, AST ≥ 2 times upper normal limit), severe fatty liver&#xD;
             disease that requires medication.&#xD;
&#xD;
          9. Clinically significant hypokalemia(less than 3.5 mmol/L) or hyperkalemia (exceeded 5.5&#xD;
             mmol/L) measured at Pre-Baseline visit (Visit2)&#xD;
&#xD;
         10. Subjects with following surgical and internal disease that may affect absorption,&#xD;
             distribution, metabolism or excretion of drugs and have conditions which include the&#xD;
             following (but are not limited to): history of major gastrointestinal surgeries&#xD;
             including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass&#xD;
             graft and stabling; current active gastritis, ulcer, gastrointestinal and rectal&#xD;
             bleeding, presence of active inflammatory bowel syndrome or biliary obstruction with&#xD;
             the past 12 months.&#xD;
&#xD;
         11. Subjects with depletion of body fluid or sodium ion not able to correct&#xD;
&#xD;
         12. Subjects with sever insulin-dependent Diabetes Mellitus(DM) or Chronic DM (HbA1c &gt; 9%&#xD;
             at Pre-Baseline visit, dosage of an oral hypoglycemic agent was modified within 12&#xD;
             weeks prior to screening visit , or currently use of active insulin treatment) or with&#xD;
             hypothyroidism not able to correct.( TSH ≥ 1.5 times upper normal limit)&#xD;
&#xD;
         13. Subjects with severe heart disease (Heart failure New York Heart Association(NYHA)&#xD;
             class 3 and 4), or history of any of the followings within the past 6 months; ischemic&#xD;
             heart disease (e.g. angina pectoris, myocardial infarction), peripheral vascular&#xD;
             disease, percutaneous transluminal coronary angioplasty, or coronary artery bypass&#xD;
             graft.&#xD;
&#xD;
         14. Subjects with clinically significant ventricular tachycardia, atrial fibrillation,&#xD;
             atrial flutter or any other clinical significant arrhythmia conditions at discretion&#xD;
             of investigator&#xD;
&#xD;
         15. Subjects with hypertrophic obstructive cardiomyopathy, severe obstructive coronary&#xD;
             artery disease, aortic stenosis, hemodynamically significant aortic valve stenosis, or&#xD;
             mitral valve stenosis.&#xD;
&#xD;
         16. Subjects with severe cerebrovascular disorder (e.g. stroke, cerebral infarction or&#xD;
             cerebral hemorrhage within the past 6 months)&#xD;
&#xD;
         17. Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory&#xD;
             therapy, past or current medical history with wasting disease, autoimmune diseases&#xD;
             (e.g. rheumatoid arthritis, systemic lupus erythematosus) or connective tissue&#xD;
             disease.&#xD;
&#xD;
         18. Subjects with known moderate or malignant retinosis (e.g. retinal hemorrhage, visual&#xD;
             disturbance or retinal microaneurysm in the past 6 months)&#xD;
&#xD;
         19. Subjects with hepatitis B (including positive test for HBsAg), hepatitis C-positive&#xD;
&#xD;
         20. Subjects with history or evidence of abusing drugs or alcohol within the past 2 years.&#xD;
&#xD;
         21. Medical history with hypersensitivity to angiotensin II antagonist based drugs or&#xD;
             HMG-CoA reductase inhibitor based drugs or any ingredient contained in these 2 drugs.&#xD;
&#xD;
         22. Medical history with clinically significant hypersensitivity to any components or&#xD;
             other drugs on the investigational product or additives (yellow 5)&#xD;
&#xD;
         23. Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency&#xD;
             or glucose-galactose malabsorption.&#xD;
&#xD;
         24. Pregnant women and lactating female.&#xD;
&#xD;
         25. Subjects planning pregnancy or childbearing potential who are not using effective&#xD;
             contraceptive methods (surgical sterilized, intrauterine (contraceptive) device/condom&#xD;
             or the combination of diaphragm and spermicidal agents)&#xD;
&#xD;
         26. Subjects who are participating in another trial or took other investigational product&#xD;
             within 12 weeks prior to Screening visit&#xD;
&#xD;
         27. Medical history of all kinds of malignant tumor including leukemia and lymphoma in the&#xD;
             past 5 years&#xD;
&#xD;
         28. A subject with other reasons not specified above that, ineligible to participate in&#xD;
             this clinical trial at discretion of study investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongjoo Oh</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul university Bundang hospital</name>
      <address>
        <city>Bundang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A university hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje Heaundai Paik hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje university Busan Paik hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChungNam university hospital</name>
      <address>
        <city>ChungNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DanGuk university hospital</name>
      <address>
        <city>Chungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic university of Korea Daegu hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DongGuk university Gyeongju hospital</name>
      <address>
        <city>Gyeongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DongGuk university Ilsan hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje university Ilsan Paik hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon university Gil medical center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha university hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju national university hospital</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JeonNam university hospital</name>
      <address>
        <city>JeonNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungbook National university hospital</name>
      <address>
        <city>Kyungbook</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeil hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea university Anam hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea university Guro hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Seoul hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul national university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic university St. Mary hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aju university hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YoungNam university hospital</name>
      <address>
        <city>YoungNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

